Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening

There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene expression between BC samples and benign tumours was used to identify candidate biomarkers for blood-based screening. We identified two proteins (Fibronectin 1 and CXCL9) from a gene e...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2010-02, Vol.102 (3), p.462-468
Main Authors: Ruiz-Garcia, E, Scott, V, Machavoine, C, Bidart, J M, Lacroix, L, Delaloge, S, Andre, F
Format: Article
Language:English
Subjects:
Adult
Biomarkers
Biomarkers, Tumor - blood
Blood & organ donations
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - diagnosis
Cancer research
Chemokine CXCL9 - blood
Chemokine CXCL9 - genetics
Clinical Study
Datasets
Drug dosages
Enzyme-Linked Immunosorbent Assay
Feasibility studies
Female
Fibronectins - blood
Fibronectins - genetics
Gene expression
Gene Expression Profiling
Humans
Mammography
Medical research
Medical screening
Middle Aged
Mortality
Proteins
Receptors, Estrogen - analysis
Tumors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene expression between BC samples and benign tumours was used to identify candidate biomarkers for blood-based screening. We identified two proteins (Fibronectin 1 and CXCL9) from a gene expression data set that included 120 BC samples and 45 benign lesions. These proteins fulfil the following criteria: differential gene expression between cancer and benign lesion, protein released in the extracellular medium and stable in the serum, commercially available ELISA kit, ELISA accuracy in a feasibility study. Protein concentrations were determined by ELISA. Blood samples were from normal volunteers (n=119) and early BC patients (n=133). Seventy-three per cent of patients had cT1-T2 tumour. Patients had higher CXCL9 and Fibronectin 1 concentrations than volunteers. CXCL9 mean concentration was 851 and 635 pg ml(-1) for patients and volunteers respectively (P=0.013). CXCL9 concentration was significantly higher in patients with estrogen receptor (ER)-negative compared with volunteers (P=0.003), data consistent with gene expression profile. Fibronectin 1 mean concentration was 190 microg ml(-1) for patients and 125 microg ml(-1) for volunteers (P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6605511